Mumbai, Feb. 12 -- Profit before tax (PBT) spiked 45.53% YoY to Rs 1,071.3 crore in Q3 FY25.

EBITDA stood at Rs 1,409.6 crore in Q3 FY25, registering a growth of 32.07%, compared with Rs 1,067.3 crore posted in Q3 FY24. EBITDA margin improved to 25.1% in Q3 FY25 as against 21% in Q3 FY24.

Revenue from North America for Q3 FY2025 sales were Rs 2,121.3 crore, up 12.32% compared to Rs 1,888.5 crore in Q3 FY2024, accounting for 38% of Lupin's global sales. U.S. Q3 FY2025 sales were $235 million compared to $212 million in Q3 FY2024.

The company continues to maintain its leadership position as the 3 rd largest pharmaceutical player in both the U.S. generics market and U.S.

India formulation sales for Q3 FY2025 sales were Rs 1,930.5 crore, ...